Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

ADMA Biologics' 4Q 2023 Preliminary Unaudited Total Revenue of $72M-74M Versus Consensus Of $68.49M; FY 2023 Preliminary Unaudited Total Revenue of $256M-258M Versus Consensus Of $252.79M

Author: Benzinga Newsdesk | January 08, 2024 09:18am

2024-2025 Financial Guidance:

FY 2024-2025 Total Revenue expected to be in the range of $320 Million to $370 Million, respectively, increased from $290 Million and $335 Million previously.
FY 2024-2025 Net Income expected to exceed $60 Million to $110 Million, respectively, increased from $55 Million and $100 Million previously.
FY 2024 Adjusted EBITDA anticipated to reach $85 Million or more.

Posted In: ADMA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION